Who to call at AINOS, INC., and when
Fundz watches for the moments AINOS, INC. starts buying, and tells you who to reach.
- An alert the day AINOS, INC. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AINOS, INC., from your own LinkedIn network
AINOS, INC.
The company signed a major contract or deal. An 8-K is the notice a US public company must file within four business days of a major event.
amarbio.comAI Executive Summary
AI-powered analysis of 8-K filing content
AINOS, INC. entered into a Global Exclusive License Agreement with BioPhoenix Co., Ltd. on September 24, 2026, granting BioPhoenix worldwide exclusive rights to develop and commercialize the VELDONA® low-dose oral interferon alpha technology platform. This strategic licensing deal expands AINOS's global market reach and revenue potential.
Key Takeaways
AINOS granted BioPhoenix an exclusive, worldwide, irrevocable, transferable and sublicensable license to VELDONA® technology
The agreement includes intellectual property and related assets associated with the low-dose oral interferon alpha platform
2 more takeaways
Related Filings (1)
1 more filing from AINOS, INC. in the last 90 days
Filing Overview
What This Means
AINOS, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.